Never Run Out Of Buyers To Sell To.
The cancer field is lacking biomarkers for personalized risk-stratification. Consequently clinical practice today is dominated by “one size fits all” strategies e.g. for treatment- and post-treatment surveillance. This is often leading to massive overtreatment and a waste of resources following up non-relapsing patients. Circulating Tumor DNA Technological advances have recently enabled development of circulating tumor DNA (ctDNA) based strategies for personal risk assessment. The ctDNA is fragments of DNA shedded from the cancer cells as the tumor grows and develops. These DNA fragments have…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$1M to $5M
Estimated OwnershipNonprofitMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.